MEDESIS PHARMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 EUR | +2.55% |
|
+13.25% | +62.44% |
| 2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 95.73K 103K | Sales 2022 | 197K 212K | Capitalization | 8.68M 9.31M |
|---|---|---|---|---|---|
| Net income 2021 | -2M -2.15M | Net income 2022 | -2M -2.15M | EV / Sales 2021 | 219 x |
| Net cash position 2021 | 1.61M 1.72M | Net Debt 2022 | 1.08M 1.15M | EV / Sales 2022 | 49.4 x |
| P/E ratio 2021 |
-8.52
x | P/E ratio 2022 |
-3.16
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 80.97% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.09% | ||
| 1 week | +9.24% | ||
| Current month | +9.68% | ||
| 1 month | +3.03% | ||
| 3 months | +74.36% | ||
| 6 months | +54.20% | ||
| Current year | +56.68% |
1 week
1.14
1.61
1 month
1.141.61
Current year
0.752.40
1 year
0.752.67
3 years
0.7510.10
5 years
0.7518.00
10 years
0.7518.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 03-04-02 | |
Solene Guilliot
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Mario Alcaraz
SEC | Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 19-06-11 | |
Robert Alonso
BRD | Director/Board Member | - | 22-10-26 |
Walt Linscott
BRD | Director/Board Member | 63 | 22-10-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 1.41 | +2.55% | 220 |
| 24-05-08 | 1.375 | +3.00% | 4,325 |
| 24-05-07 | 1.335 | -4.64% | 5,533 |
| 24-05-06 | 1.4 | +16.67% | 36,447 |
| 24-05-03 | 1.2 | -3.61% | 5,794 |
Real-time Euronext Paris, May 09, 2024 at 04:09 am EDT
More quotes
Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.
The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).
| 1st Jan change | Capi. | |
|---|---|---|
| +56.68% | 6.54M | |
| +2.93% | 108B | |
| -4.40% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- ALMDP Stock